Mostrando 3 resultados de: 3
Filtros aplicados
Subtipo de publicación
Article(3)
Publisher
Clinical Cancer Research(1)
Endocrinology(1)
Proceedings of the National Academy of Sciences of the United States of America(1)
Área temáticas
Enfermedades(3)
Origen
scopus(3)
3β-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer
ArticleAbstract: Prostate cancer usually responds to androgen deprivation therapy, although the response in metastatiPalabras claves:Autores:Evaul K., Li R., Papari-Zareei M., Richard J. Auchus, Sharifi N.Fuentes:scopusAbiraterone inhibits 3β-hydroxysteroid dehydrogenase: A rationale for increasing drug exposure in castration-resistant prostate cancer
ArticleAbstract: Purpose: Treatment with abiraterone (abi) acetate prolongs survival in castration-resistant prostatePalabras claves:Autores:Chang K.H., Evaul K., Li R., Liu J., Richard J. Auchus, Sharifi N., Sharma K.K., Yoshimoto J.A.Fuentes:scopusDihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer
ArticleAbstract: In the majority of cases, advanced prostate cancer responds initially to androgen deprivation therapPalabras claves:5-alpha-androstanedione, Abiraterone acetate, Hormonal therapy, Hormone resistance, Tumor metabolismAutores:Chang K.H., Li R., Papari-Zareei M., Richard J. Auchus, Sharifi N., Watumull L., Zhao Y.Fuentes:scopus